01—Abstract
Summary
Summary of the 10-Q filed August 1, 2025. Cited figures are marked; the original filing is the authoritative source.
Thermo Fisher Scientific Inc. reported solid revenue growth in the second quarter and first half of 2025, driven by strong performance in its Life Sciences Solutions and Laboratory Products and Biopharma Services segments.
While overall revenue increased by 3% and 2% respectively for the periods, the company's profitability metrics showed some mixed signals. Operating income saw marginal increases, but operating income margins experienced slight declines, attributed to unfavorable business mix, strategic investments, and tariff impacts. The company also announced a significant pending acquisition of Solventum Corporation's Purification and Filtration business for approximately $4.0 billiona, expected to close by year-end 2025, which will further bolster the Life Sciences Solutions segment.
Despite a slight decrease in free cash flow compared to the prior year, driven by increased debt issuance and share repurchases, Thermo Fisher maintains a strong liquidity position and expects to meet its cash requirements. The company continues to execute its growth strategy focused on innovation, customer partnerships, and its commercial engine, while managing costs through productivity improvements and restructuring efforts. Investors should monitor the integration of recent and pending acquisitions and the ongoing impact of global economic conditions on customer spending, particularly in the Analytical Instruments segment.
02—Key points
Key Highlights
- Total revenues increased by 3% to $10.86 billion for the three months ended June 28, 2025, and by 2% to $21.22 billion for the six months ended June 28, 2025.
- Operating income saw a modest increase of 1% to $1.83 billion for the quarter and 2% to $3.55 billion for the six months, though operating margin slightly decreased due to business mix and strategic investments.
- The company announced a pending acquisition of Solventum Corporation's Purification and Filtration business for approximately $4.0 billion, expected to close by the end of 2025.
- Free cash flow for the first six months of 2025 was $1.48 billion, a decrease from $2.58 billion in the prior year, reflecting higher debt issuance and share repurchases.
- The Life Sciences Solutions segment reported strong revenue growth of 6% for the quarter and 4% for the six months, driven by the bioproduction business and the Olink acquisition.
- The Analytical Instruments segment experienced revenue declines of 3% for the quarter and 1% for the six months, attributed to tariffs and reduced demand from academic and government customers.
- Thermo Fisher repurchased $2.00 billion of its common stock in the first six months of 2025 and has a new authorization to repurchase up to $4.00 billion.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed August 1, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $10.86B$10.54B | +3.0% |
| R&D Expenses | $352.00M$339.00M | +3.8% |
| SG&A Expenses | $2.14B$2.11B | +1.4% |
| Operating Expenses | $9.02B$8.72B | +3.4% |
| Operating Income | $1.83B$1.82B | +0.8% |
| Net Income | $1.62B$1.55B | +4.2% |
| EPS (Basic) | $4.28$4.05 | +5.7% |
| EPS (Diluted) | $4.28$4.04 | +5.9% |
| Shares Outstanding (Basic) | 378.00M382.00M | −1.0% |
| Shares Outstanding (Diluted) | 378.00M383.00M | −1.3% |
05—Questions
Frequently Asked Questions
What is the financial performance of Thermo Fisher Scientific for the reported quarter?
For the three months ended June 28, 2025, Thermo Fisher Scientific reported total revenues of $10.86 billion, a 3% increase compared to the prior year. Operating income was $1.83 billion, a 1% increase, while diluted earnings per share were $4.28, up 6% from $4.04 in the prior year. The company noted slight decreases in operating income margins due to business mix and strategic investments.
What are the key growth drivers and challenges highlighted in the report?
Key growth drivers include strong demand from pharmaceutical and biotech customers, particularly in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments. Challenges include muted demand for instruments in academic and government markets due to economic uncertainty and tariffs, and headwinds in the China market impacting the diagnostics and healthcare sector.
What significant acquisitions or divestitures were mentioned?
Thermo Fisher announced a pending acquisition of Solventum Corporation's Purification and Filtration business for approximately $4.0 billion, expected to close by the end of 2025. This acquisition is expected to strengthen the Life Sciences Solutions segment. The company also completed the acquisition of Olink Holding AB in July 2024, which is contributing to growth in the Life Sciences Solutions segment.
How is the company managing its capital and liquidity?
The company has a strong liquidity position, with $4.58 billion in cash and cash equivalents as of June 28, 2025. Free cash flow for the first six months was $1.48 billion. The company continues to return capital to shareholders through share repurchases, having repurchased $2.00 billion in the first six months of 2025, and dividends. Thermo Fisher believes its current cash, cash equivalents, operating cash flow, and available credit facilities will be sufficient to meet its future cash requirements.
06—Continue